Oğuzcan Kınıkoğlu

29PUBLICATIONS
138CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 28, 2026
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

|Apr 14, 2026
Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study.

Anıl Yıldız, Oguzcan Kınıkoğlu

|Mar 28, 2026
Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR.

Ayberk Bayramgil, Mehmet Haluk Yücel, Ezgi Turkoglu

|Mar 14, 2026
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Jan 28, 2026
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study.

Ugur Ozkerim, Oguzcan Kinikoglu, Sila Oksuz

Pageof 5

Frequent Collaborators

22 joint publications

Deniz Işık

22 joint publications

Hatice Odabas

20 joint publications

Nedim Turan

19 joint publications

Heves Surmeli